Log in

Haemonetics Stock Price, Forecast & Analysis (NYSE:HAE)

$120.47
+0.62 (+0.52 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$119.64
Now: $120.47
$121.88
50-Day Range
$118.89
MA: $124.06
$129.46
52-Week Range
$80.24
Now: $120.47
$140.36
Volume246,809 shs
Average Volume326,910 shs
Market Capitalization$6.11 billion
P/E Ratio50.41
Dividend YieldN/A
Beta0.77
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.58 million
Cash Flow$4.66 per share
Book Value$11.52 per share

Profitability

Net Income$55.02 million

Miscellaneous

Employees3,216
Market Cap$6.11 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.


Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics declared that its Board of Directors has initiated a share repurchase plan on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its earnings results on Tuesday, August, 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $0.17. The medical instruments supplier had revenue of $229.35 million for the quarter, compared to analysts' expectations of $219.52 million. Haemonetics had a return on equity of 24.59% and a net margin of 6.90%. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY20 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.09. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for HAE?

5 brokerages have issued 12 month price targets for Haemonetics' shares. Their forecasts range from $140.00 to $150.00. On average, they anticipate Haemonetics' share price to reach $144.80 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View Analyst Price Targets for Haemonetics.

What is the consensus analysts' recommendation for Haemonetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Has Haemonetics been receiving favorable news coverage?

Media stories about HAE stock have trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Haemonetics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Haemonetics.

Are investors shorting Haemonetics?

Haemonetics saw a decline in short interest in October. As of October 31st, there was short interest totalling 717,000 shares, a decline of 13.3% from the September 30th total of 826,800 shares. Based on an average daily volume of 337,600 shares, the short-interest ratio is currently 2.1 days. Approximately 1.4% of the shares of the company are sold short. View Haemonetics' Current Options Chain.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), CA (CA), NVIDIA (NVDA) and Nexstar Media Group (NXST).

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (1.17%), Fisher Asset Management LLC (0.47%), Russell Investments Group Ltd. (0.45%), Emerald Advisers LLC (0.40%), Emerald Mutual Fund Advisers Trust (0.35%) and Rhumbline Advisers (0.31%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Picton Mahoney Asset Management, Morse Asset Management Inc, Rhumbline Advisers, Systematic Financial Management LP, Baldwin Brothers Inc. MA, New York State Teachers Retirement System, Russell Investments Group Ltd. and Pacer Advisors Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

Which institutional investors are buying Haemonetics stock?

HAE stock was acquired by a variety of institutional investors in the last quarter, including Cookson Peirce & Co. Inc., Public Employees Retirement Association of Colorado, Lisanti Capital Growth LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, First Trust Advisors LP, Catalyst Capital Advisors LLC and Mackay Shields LLC. View Insider Buying and Selling for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $120.47.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $6.11 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

What is Haemonetics' official website?

The official website for Haemonetics is http://www.haemonetics.com/.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (NYSE HAE)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  380 (Vote Underperform)
Total Votes:  665
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel